Unknown

Dataset Information

0

Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma.


ABSTRACT: Transarterial chemoembolization (TACE) is the standard procedure for treating Barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma (HCC). However, it is often carried out in the treatment of BCLC stage 0/A HCC for various reasons. This study aimed to elucidate the prognosis for BCLC stage 0/A HCC patients treated with TACE or with radiofrequency ablation (RFA).The prognosis of 242 BCLC stage 0/A HCC patients within Milan criteria who underwent initially TACE or RFA were retrospectively analyzed using propensity score matching analysis.The analyses of baseline patient characteristics revealed that the maximum tumor size and the proportion of BCLC stage A patients were significantly higher in patients treated with TACE than in those treated with RFA (P<0.001 and 0.047, respectively). After adjusting these factors using propensity score matching (1:3 matching), patients treated with TACE (n=32) and those treated with RFA (n=96) were further analyzed. The local recurrence rate was significantly higher in the TACE group than in the RFA group (P<0.001). However, the overall survival (OS) in HCC patients treated with TACE was comparable to that in HCC patients treated with RFA (1 year, 93.5 vs. 95.8%; 3 years, 75.4 vs. 85.8%; 5 years, 61.8 vs. 70.7%; P=0.196). Multivariate analyses followed by univariate analyses revealed that serum bilirubin level (P=0.032), serum albumin level (P=0.008), HBV-DNA (P=0.013), and tumor number (P=0.021) were independent predictors of OS.TACE can substitute RFA at least in some patients with BCLC 0/A HCC.

SUBMITTER: Ishikawa K 

PROVIDER: S-EPMC5940395 | biostudies-other | 2018 Apr

REPOSITORIES: biostudies-other

altmetric image

Publications

Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma.

Ishikawa Kentaro K   Chiba Tetsuhiro T   Ooka Yoshihiko Y   Suzuki Eiichiro E   Ogasawara Sadahisa S   Maeda Takahiro T   Yokoyama Masayuki M   Inoue Masanori M   Wakamatsu Toru T   Kusakabe Yuko Y   Saito Tomoko T   Tawada Akinobu A   Arai Makoto M   Kanda Tatsuo T   Maruyama Hitoshi H   Imazeki Fumio F   Kato Naoya N  

Oncotarget 20180420 30


<h4>Background and aim</h4>Transarterial chemoembolization (TACE) is the standard procedure for treating Barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma (HCC). However, it is often carried out in the treatment of BCLC stage 0/A HCC for various reasons. This study aimed to elucidate the prognosis for BCLC stage 0/A HCC patients treated with TACE or with radiofrequency ablation (RFA).<h4>Materials and methods</h4>The prognosis of 242 BCLC stage 0/A HCC patients within Milan c  ...[more]

Similar Datasets

| S-EPMC8084693 | biostudies-literature
| S-EPMC6766138 | biostudies-literature
| S-EPMC10650828 | biostudies-literature
| S-EPMC7324959 | biostudies-literature
| S-EPMC3923023 | biostudies-literature
| S-EPMC7105822 | biostudies-literature
| S-EPMC5506745 | biostudies-other
| S-EPMC8340149 | biostudies-literature
| S-EPMC7785216 | biostudies-literature
| S-EPMC4346053 | biostudies-other